Future Oncology
Papers 4,076
1 page of 408 pages (4,076 results)
#1Betül İbiş (Istanbul University)
#2Mario Tiribelli (University of Udine)H-Index: 32
Last. Ahmet Emre Eskazan (Istanbul University)H-Index: 15
view all 3 authors...
#1Fangqun Chang (Anhui Medical University)
#2Hao Zhang (Anhui Medical University)
Last. Yanbei Zhang (Anhui Medical University)
view all 7 authors...
Objective: D-dimer is correlated to the poor prognosis of non-small cell lung cancer. The study aimed to investigate the association between plasma D-dimer and concomitant mutations in non-small cell lung cancer. Methods: A total of 517 non-small cell lung cancer patients were recruited and tested for ALK, BRAF, EGFR, HER2/ERBB2, KRAS, MET, PIK3CA, RET and ROS1 mutation by next-generation sequencing. Multiple gene mutation information, clinical baseline data and laboratory test data were analyze...
#1Jens Benn SørensenH-Index: 34
#2Pia HorvatH-Index: 10
Last. Simon Ekman (Karolinska University Hospital)H-Index: 12
view all 12 authors...
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/II...
#1Max S. ManoH-Index: 16
#2Fadil ÇitakuH-Index: 2
Last. Paul Barach (WSU: Wayne State University)H-Index: 14
view all 3 authors...
The healthcare industry compares unfavorably with other ultra-safe industries such as aviation and nuclear power plants, which address complexity by reducing the vulnerability of a single person and promoting teams and strong systems. A multidisciplinary tumor board (MTB) is an evidence-based organizational approach to implementing a more effective concept in oncology practice. Studies addressing the correlation between MTBs and cancer outcomes show promising results, and other potential benefit...
#1Tomer M Mark (University of Colorado Denver)H-Index: 24
Last. Jonathan KishH-Index: 16
view all 3 authors...
Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materials & methods: US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥ very good partial response) and progression-free survival were compared. Results: Disease response was 78.6 and 51.7% for pomalidomide (...
#1Wenjing Li (Fudan University)
Last. Feng Long (Fudan University)
view all 4 authors...
Background: The efficacy of PD-1 or PD-L1 inhibitors in patients with brain metastases of non-small-cell lung cancer (BM-NSCLC) is inconclusive. Materials & methods: An electronic search was performed. Randomized controlled trials RCTs that compared the efficacy of PD-1- or PD-L1-inhibitor-based regimens with non-PD-1/L1 inhibitor regimens in patients with NSCLC and reported the data of subgroup patients with brain metastases were eligible for inclusion. The hazard ratios (HRs) for progression-f...
#1Jing-Zhou Hou (University of Pittsburgh)H-Index: 9
#2Kellie Ryan (AstraZeneca)H-Index: 6
Last. Hannah Le (AstraZeneca)H-Index: 2
view all 10 authors...
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one...
#1Zhen-Hua Wang (NCU: Nanchang University)
#2Xiaoping Tang (NCU: Nanchang University)
Last. Xin-Lan Xiao (NCU: Nanchang University)
view all 8 authors...
Objective: To verify the association between CD44 and CD133 expression levels and the prognosis of patients with lower-grade gliomas (LGGs) and constructing radiomic models to predict those two genes' expression levels before surgery. Materials & methods: Genomic data of patients with LGG and the corresponding T2-weighted fluid-attenuated inversion recovery images were downloaded from the Cancer Genome Atlas and the Cancer Imaging Archive, which were utilized for prognosis analysis, radiomic fea...
#1Shasha Wang (Peking Union Medical College)H-Index: 1
#2Rongrong Luo (Peking Union Medical College)H-Index: 1
Last. Xiaohong Han (Peking Union Medical College Hospital)H-Index: 3
view all 4 authors...
Background: Recent studies showed that ALK-fusion variants are associated with heterogeneous clinical outcomes. However, contradictory conclusions have been drawn in other studies showing no correlation between ALK variants and prognoses. Methods: A systematic review and meta-analysis was performed to evaluate the prognostic value of EML4-ALK fusion variants for patient outcomes. Results: 28 studies were included in the analysis. According to the pooled results, patients harboring variant 1 show...
#1Tae Won Kim (Asan Medical Center)H-Index: 17
#2Julien Taieb (University of Paris)H-Index: 58
Last. Takayuki YoshinoH-Index: 57
view all 6 authors...
Oxaliplatin-based chemotherapy with a regimen such as FOLFOX with or without targeted therapy is a standard of care option for advanced colorectal cancer; however, long-term exposure to oxaliplatin is associated with cumulative toxicity. Growing evidence suggests maintenance therapy with a less intensive regimen after platinum-based induction therapy can provide continuing benefit with reduced toxicity. We describe the rationale and design of the Phase III LYNK-003 trial, which will evaluate the...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.